Newswire (Published: Thursday, December 20, 2018, 12:01:00 PM CST, Received: Thursday, December 20, 2018, 2:27:36 PM CST)
Word Count: 360
Accurate primary staging is imperative to develop individualized treatment strategies for those with prostate cancer. Currently, prediction tools--or nomograms--assess a variety of factors to determine risk of advanced disease: prostate-speci?c antigen value at diagnosis, Gleason score, and others. While these nomograms offer an estimate of probability, they do not specifically indicate the extent of disease, which can be obtained using molecular imaging.
To compare the performance 68Ga-PSMA-11 PET/MRI with clinical nomograms, researchers conducted a retrospective study including 73 patients. Each patient's risk for advanced disease was predicted using the
In each of the three advanced disease types analyzed (LNM, ECE and SVI), 68Ga-PSMA-11 PET/MRI resulted in an equivalent positivity rate compared with the MSKCC nomogram and the Partin tables. On a patient base, the sensitivity and specificity for 68Ga-PSMA-11 PET/MRI were also comparable to that of the other methodologies for the three disease types. Overall, a trend towards higher prediction of the final T and N stages on a patient base was noticed for PSMA-targeted molecular imaging.
"Our results showed that PSMA-targeted PET/MRI performed equally well to established clinical nomograms for preoperative staging in high-risk prostate cancer patients and provided additional information on tumor location" noted Andrei Gafita, MD. "Translated into a clinical setting, the use of this imaging technique for preoperative staging might support treatment planning that may lead to improved patient outcomes."
(Our reports deliver fact-based news of research and discoveries from around the world.)